(Q45883534)

17 December 2017

title

Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results (English)

1 reference

17 December 2017

0 references

0 references

1 reference

2

Luisa Barzon

1 reference

17 December 2017

8

Giorgio Palù

1 reference

17 December 2017

4

Monia Pacenti

1 reference

17 December 2017

Elisa Franchin

3

object named as

Elisa Franchin

1 reference

17 December 2017

author name string

Federico Colombo

1

1 reference

17 December 2017

Vittore Pinna

5

1 reference

17 December 2017

Daniela Danieli

6

1 reference

17 December 2017

Mariano Zanusso

7

1 reference

17 December 2017

publication date

1 October 2005

1 reference

17 December 2017

published in

Cancer Gene Therapy

1 reference

17 December 2017

volume

12

1 reference

17 December 2017

page(s)

835-848

1 reference

17 December 2017

issue

10

1 reference

17 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700851

exact match

0 references

cites work

Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

Endocrine aspects of cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

Influence of the bystander effect on HSV-tk/GCV gene therapy. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

Systemic activation of the immune system during ganciclovir treatment following intratumoral herpes simplex virus type 1 thymidine kinase gene transfer in an adolescent ependymoma patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

Production and characterization of a bicistronic Moloney-based retroviral vector expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

Transcriptionally targeted retroviral vector for combined suicide and immunomodulating gene therapy of thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and herpes simplex virus thymidine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

Gene stereotactic neurosurgery for recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

The prothrombotic state in cancer: pathogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

A Phase I/II Study of Herpes Simplex Virus Type 1 Thymidine Kinase “Suicide” Gene Therapy for Recurrent Glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

High-titer packaging cells producing recombinant retroviruses resistant to human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700851

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.CGT.7700851

1 reference

17 December 2017

Dimensions Publication ID

0 references

1 reference

17 December 2017